Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 6;20(1):19.
doi: 10.1186/s13014-025-02595-x.

Local control and recurrence patterns after stereotactic irradiation delivered in more than 4 fractions for hepatocellular carcinomas and liver metastases: a retrospective study

Alizée Renan  1   2 , Marie Bruand  3   4 , Maria Jolnerovski  3 , Aboubacar Diallo  5 , Nicolas Demogeot  3
Affiliations

Local control and recurrence patterns after stereotactic irradiation delivered in more than 4 fractions for hepatocellular carcinomas and liver metastases: a retrospective study

Alizée Renan et al. Radiat Oncol. .

Abstract

Background: Stereotactic Body Radiation Therapy (SBRT) is a safe and effective treatment for liver metastases or hepatocellular carcinoma (HCC) with a dose-response relationship for local control (LC). Proximity to organs at risk (OAR) often requires dose de-escalation. This study evaluated LC and recurrence patterns in patients administered hepatic SBRT in more than 4 fractions due to dosimetric constraints.

Methods: This retrospective study included 33 patients treated with SBRT (Cyberknife®) in more than 4 fractions for HCC or liver metastases, between January 2011 and December 2019. Patients were ineligible for treatment in 3 or 4 fractions due to OAR proximity. Recurrence patterns were analysed according to the volume shared between recurrence and initial target or treatment isodose volumes.

Results: The primary dose ranged from 35 to 50 Gy delivered in 5 to 7 fractions for the treatment of HCC (39%) or liver metastases (61%) mainly secondary to colorectal cancer (40%). LC rate was 64%, with 12 patients showing recurrence volume overlap with the initial target volume or treatment isodose. In-field recurrence occurred in only 12.5% of patients with most relapses being out-of-field. No grade ≥ 3 events were reported.

Conclusion: Despite dose reductions to spare OAR, SBRT showed satisfactory LC with low toxicity. Out-of-field recurrence remains the most common pattern identified and likely related to underlying disease. Prospective data are necessary to determine whether preserving dose while reducing planning target volume (PTV) coverage could enhance LC. Trial registration All patients were retrospectively registered, and this study is registered at the Health Data Hub site (number HDH414).

Keywords: Dosimetric constraints; Hepatocellular carcinoma; Liver metastases; Local control; SBRT.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was approved by the National Commission for Information Technology and Civil Liberties (CNIL) and registered with the French data protection authority. Clinical trial number: Not applicable. Consent to Participate: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Volumes delineation. A, Planning-CT: initial Gross Tumour Volume (GTVi: red), initial Clinical Target Volume (CTVi: magenta), initial Planning Target Volume (PTVi: dark blue), isodose 80% (light blue), isodose 70% (cyan), isodose 50% (green). B, Recurrence MRI: volumes of recurrence (GTVr: red). C, Recurrence MRI: shared volume GTVr-PTVi (filled brown), shared volume GTVr-isodose 80% (filled yellow), GTVr (red), PTVi (dark blue), isodose 80% (light blue), isodose 70% (cyan), isodose 50% (green)
Fig. 2
Fig. 2
PFS, IHPFS and IRFS. A—Progression Free Survival (PFS); 2.B—Intrahepatic Progression Free Survival (IHPFS); and 2.C—In-field recurrence free survival (IRFS); with red points indicating data at 6 months, 1 year, and 2 years post-treatment
See this image and copyright information in PMC

References

    1. Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, et al. Curative irradiation treatment of hepatocellular carcinoma: a multicenter phase 2 trial. Int J Radiat Oncol Biol Phys. 2020;107(1):116–25. - PubMed
    1. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:238–55. - PubMed
    1. Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D’Ambrosio D, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol Lond Engl. 2018;13(1):26. - PMC - PubMed
    1. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681–93. - PMC - PubMed
    1. Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):541–65. - PubMed

MeSH terms

LinkOut - more resources